Cargando…

Epigenetic associations in relation to cardiovascular prevention and therapeutics

Cardiovascular diseases (CVD) increasingly burden societies with vast financial and health care problems. Therefore, the importance of improving preventive and therapeutic measures against cardiovascular diseases is continually growing. To accomplish such improvements, research must focus particular...

Descripción completa

Detalles Bibliográficos
Autor principal: Voelter-Mahlknecht, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714496/
https://www.ncbi.nlm.nih.gov/pubmed/26779291
http://dx.doi.org/10.1186/s13148-016-0170-0
_version_ 1782410333282893824
author Voelter-Mahlknecht, Susanne
author_facet Voelter-Mahlknecht, Susanne
author_sort Voelter-Mahlknecht, Susanne
collection PubMed
description Cardiovascular diseases (CVD) increasingly burden societies with vast financial and health care problems. Therefore, the importance of improving preventive and therapeutic measures against cardiovascular diseases is continually growing. To accomplish such improvements, research must focus particularly on understanding the underlying mechanisms of such diseases, as in the field of epigenetics, and pay more attention to strengthening primary prevention. To date, preliminary research has found a connection between DNA methylation, histone modifications, RNA-based mechanisms and the development of CVD like atherosclerosis, cardiac hypertrophy, myocardial infarction, and heart failure. Several therapeutic agents based on the findings of such research projects are currently being tested for use in clinical practice. Although these tests have produced promising data so far, no epigenetically active agents or drugs targeting histone acetylation and/or methylation have actually entered clinical trials for CVDs, nor have they been approved by the FDA. To ensure the most effective prevention and treatment possible, further studies are required to understand the complex relationship between epigenetic regulation and the development of CVD. Similarly, several classes of RNA therapeutics are currently under development. The use of miRNAs and their targets as diagnostic or prognostic markers for CVDs is promising, but has not yet been realized. Further studies are necessary to improve our understanding of the involvement of lncRNA in regulating gene expression changes underlying heart failure. Through the data obtained from such studies, specific therapeutic strategies to avoid heart failure based on interference with incRNA pathways could be developed. Together, research and testing findings raise hope for enhancing the therapeutic armamentarium. This review presents the currently available data concerning epigenetic mechanisms and compounds involved in cardiovascular diseases, as well as preventive and therapeutic approaches against them.
format Online
Article
Text
id pubmed-4714496
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47144962016-01-16 Epigenetic associations in relation to cardiovascular prevention and therapeutics Voelter-Mahlknecht, Susanne Clin Epigenetics Review Cardiovascular diseases (CVD) increasingly burden societies with vast financial and health care problems. Therefore, the importance of improving preventive and therapeutic measures against cardiovascular diseases is continually growing. To accomplish such improvements, research must focus particularly on understanding the underlying mechanisms of such diseases, as in the field of epigenetics, and pay more attention to strengthening primary prevention. To date, preliminary research has found a connection between DNA methylation, histone modifications, RNA-based mechanisms and the development of CVD like atherosclerosis, cardiac hypertrophy, myocardial infarction, and heart failure. Several therapeutic agents based on the findings of such research projects are currently being tested for use in clinical practice. Although these tests have produced promising data so far, no epigenetically active agents or drugs targeting histone acetylation and/or methylation have actually entered clinical trials for CVDs, nor have they been approved by the FDA. To ensure the most effective prevention and treatment possible, further studies are required to understand the complex relationship between epigenetic regulation and the development of CVD. Similarly, several classes of RNA therapeutics are currently under development. The use of miRNAs and their targets as diagnostic or prognostic markers for CVDs is promising, but has not yet been realized. Further studies are necessary to improve our understanding of the involvement of lncRNA in regulating gene expression changes underlying heart failure. Through the data obtained from such studies, specific therapeutic strategies to avoid heart failure based on interference with incRNA pathways could be developed. Together, research and testing findings raise hope for enhancing the therapeutic armamentarium. This review presents the currently available data concerning epigenetic mechanisms and compounds involved in cardiovascular diseases, as well as preventive and therapeutic approaches against them. BioMed Central 2016-01-15 /pmc/articles/PMC4714496/ /pubmed/26779291 http://dx.doi.org/10.1186/s13148-016-0170-0 Text en © Voelter-Mahlknecht. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Voelter-Mahlknecht, Susanne
Epigenetic associations in relation to cardiovascular prevention and therapeutics
title Epigenetic associations in relation to cardiovascular prevention and therapeutics
title_full Epigenetic associations in relation to cardiovascular prevention and therapeutics
title_fullStr Epigenetic associations in relation to cardiovascular prevention and therapeutics
title_full_unstemmed Epigenetic associations in relation to cardiovascular prevention and therapeutics
title_short Epigenetic associations in relation to cardiovascular prevention and therapeutics
title_sort epigenetic associations in relation to cardiovascular prevention and therapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714496/
https://www.ncbi.nlm.nih.gov/pubmed/26779291
http://dx.doi.org/10.1186/s13148-016-0170-0
work_keys_str_mv AT voeltermahlknechtsusanne epigeneticassociationsinrelationtocardiovascularpreventionandtherapeutics